BiotechTube
Home/Pipeline/Additional Carrier Program 2

Additional Carrier Program 2

Not specified

Pre-clinicalActive

Key Facts

Indication
Not specified
Phase
Pre-clinical
Status
Active
Company
Ten Boron

About Ten Boron

Tenboron is a Finnish biotech pioneering next-generation carriers for Boron Neutron Capture Therapy (BNCT), a targeted radiotherapy. The company is advancing a clinical-stage pipeline led by TB0010, an antibody-boron conjugate for recurrent head and neck cancer, with Phase 1b trials on the horizon. Founded in 2010, it leverages a seasoned leadership team with deep experience in oncology drug development and BNCT. Tenboron operates as a private, pre-revenue entity, relying on partnerships for manufacturing and clinical research.

View full company profile

Therapeutic Areas

Oncology

Other Not specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved